Helen A. Mintz-Hittner, M http://tadora.org/tips-on-how-to-find-the-best-ed-medications.html .D., Kathleen A. Kennedy, M.D., M.P.H., and Alice Z. Chuang, Ph.D. For the BEAT-ROP Cooperative Group: Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity Retinopathy of prematurity can be a neovascular retinal disorder of childhood that triggers loss of vision through macular dragging and retinal detachment.1 The incidence of blindness in infants because of retinopathy of prematurity is relatively low, about 1 case in 820 infants,2 due to good neonatal care and appropriate treatment and screening. The world-wide prevalence of blindness due to retinopathy of prematurity is definitely 50,000.1 Retinal vascularization on the internal retinal surface begins at the optic nerve at 16 weeks’ gestation and proceeds anteriorly, reaching the edge of the temporal retina at 40 weeks’ gestation.

Cynthia St. Hilaire, Ph.D., Shira G. Ziegler, B.A., Thomas C. Markello, M.D., Ph.D., Alfredo Brusco, Ph.D., Catherine Groden, M.S., Fred Gill, M.D., Hannah Carlson-Donohoe, B.A., Robert J. Lederman, M.D., Marcus Y. Chen, M.D., Dan Yang, M.D., Ph.D., Michael P. Siegenthaler, M.D., Carlo Arduino, M.D., Cecilia Mancini, M.Sc., Bernard Freudenthal, M.D., Horia C. Stanescu, M.D., Anselm A. Zdebik, M.D., Ph.D., R. Krishna Chaganti, M.D., Robert L. Nussbaum, M.D., Robert Kleta, M.D., Ph.D., William A. Gahl, M.D., Ph.D., and Manfred Boehm, M.D.: NT5E Mutations and Arterial Calcifications.